---
layout: default
title: Sodium Feredetate
parent: Model Prediction Only (L5)
nav_order: 772
evidence_level: L5
indication_count: 10
---

# Sodium Feredetate
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Sodium Feredetate: From Iron Deficiency Anemia to Bronchitis

## One-Sentence Summary

> Sodium feredetate is an iron chelate compound conventionally used to treat iron deficiency anemia.
> The TxGNN model predicts it may be effective for **Bronchitis**,
> but this prediction is currently supported by **0 clinical trials** and **0 publications** — it is a pure knowledge-graph similarity score with no mechanistic or clinical corroboration.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Iron deficiency anemia (per known drug class use; not documented in India regulatory data) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 97.45% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Sodium feredetate. Based on known information, it is an iron chelate compound used as an iron replacement therapy for iron deficiency anemia. Its efficacy in that indication is well established, but there is no known pharmacological pathway linking iron chelation/supplementation to the inflammatory or infectious processes underlying bronchitis.

The model's own repurposing rationale is explicit on this point: it states that no mechanistic hypothesis supports this prediction, and that the score reflects node proximity within the TxGNN knowledge graph embedding rather than a causal or therapeutic relationship.

Notably, this internal inconsistency extends across the full top-10 candidate list for this drug: several lower-ranked predictions (gastroduodenitis, peptic ulcer disease) point in the *opposite* direction — oral iron supplementation is a well-documented cause of gastrointestinal mucosal irritation, meaning the same drug is simultaneously flagged as a candidate "treatment" for conditions it is known to potentially cause or worsen. This pattern should be treated as a strong signal that the current prediction set reflects embedding similarity rather than biological plausibility, and warrants no action beyond monitoring.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## India Market Information

Sodium feredetate is not currently marketed in India, and no product registrations are on record (0 licenses).

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: TFDA-equivalent label warnings/contraindications are currently a data gap, classified as Blocking — see Conclusion below.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- This is an L5 prediction (model score only, no clinical trials or literature) with an explicitly stated absence of mechanistic support, and internally contradictory signals elsewhere in the same candidate list. Regulatory safety data (warnings/contraindications) needed for even a preliminary safety screen (S1) is also missing, making this candidate not eligible to advance beyond S0.

**To proceed, the following is needed:**
- Local regulatory label data (warnings, contraindications) — currently blocking (DG001)
- Confirmed mechanism of action from DrugBank or primary literature (DG002)
- Any preclinical or mechanistic study connecting iron chelation to respiratory/bronchial inflammation
- At minimum one case report, observational study, or registered trial before reconsidering evidence level above L5
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

